转移性去势抵抗性前列腺癌卡巴他赛治疗的综合预后评分:CABASTY事后分析及两项国际三期试验验证
基于CABASTY随机试验的事后分析,构建并验证了用于接受卡巴他赛治疗的转移性去势抵抗性前列腺癌患者的预后评分cabascore。CABASTY队列194例中,有利、中间、不良预后组中位总生存分别为21.6、12.5、6.2个月;PROSELICA(n=1175)和CARD(n=126)卡巴他赛暴露人群验证了有利组总生存显著优于中间和不良组。CARD总体人群中,有利组卡巴他赛较ARPI改善总生存(p=0.003),中间和不良组未见改善。
要点
- cabascore基于ECOG体能状态、转移部位数、PSA、LDH、ALP和血红蛋白构建。
- CABASTY中有利、中间、不良组中位OS分别为21.6、12.5、6.2个月。
- CARD有利组卡巴他赛较ARPI改善OS(p=0.003),中间和不良组未改善。
核心结论
- cabascore可能有助于为mCRPC患者制定个体化治疗策略。
- 探索性分析提示有利预后患者接受卡巴他赛较二线ARPI获益更大。
研究设计与样本
- CABASTY随机试验的事后分析,纳入194例患者,基于多变量Cox模型风险比构建cabascore。
- 采用log-rank优化阈值将人群分为有利、中间、不良三组。
- 使用三期CARD和PROSELICA试验数据验证。
主要发现
- CABASTY中有利、中间、不良组中位OS分别为21.6、12.5、6.2个月。
- 中间vs有利:HR=2.14,95%CI=1.41-3.25,p<0.001;不良vs有利:HR=5.41,95%CI=3.42-8.72,p<0.001。
- PROSELICA(n=1175)和CARD(n=126)卡巴他赛暴露人群中,有利组中位OS显著长于中间和不良组(均p<0.001)。
- CARD总体人群(n=250)中,有利组卡巴他赛较ARPI改善OS(p=0.003),中间和不良组未见改善。
关键数值与推荐
- 模型变量包括基线ECOG体能状态(0 vs 1-2)、转移部位数(<2 vs ≥2)、PSA、LDH、ALP和血红蛋白。
临床怎么用
- cabascore可用于接受卡巴他赛的mCRPC患者预后分层。
- 有利预后患者可能优先考虑卡巴他赛而非二线ARPI。
局限性
- CABASTY分析为事后分析。
- cabascore的预测性分析为探索性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Optimal therapy after docetaxel and an androgen receptor pathway inhibitor (ARPI) in metastatic castration-resistant prostate cancer (mCRPC) remains debated. We aimed to build and validate the cabascore, a prognostic and predictive score for patients with mCRPC receiving cabazitaxel, to guide treatment strategy. METHODS: In this post hoc analysis of the randomized CABASTY trial, the cabascore was derived from multivariable Cox model hazard ratios for overall survival (OS). The population was stratified into three groups using log-rank optimization for score thresholds. Data from the phase 3 CARD and PROSELICA clinical trials were used for validation. KEY FINDINGS AND LIMITATIONS: A total of 194 patients from CABASTY were included. Model variables were baseline Eastern Cooperative Oncology Group performance status (0 versus 1-2), metastatic sites (<2 vs ≥2), prostate-specific antigen, lactate dehydrogenase, alkaline phosphatase, and hemoglobin. Median OS was 21.6, 12.5, and 6.2 mo for cabascore-determined favorable, intermediate, and poor prognostic subgroups, respectively (intermediate versus favorable: hazard ratio (HR) = 2.14; 95% confidence interval (CI) = 1.41-3.25; p < 0.001; poor versus favorable: HR = 5.41; 95% CI = 3.42-8.72; p < 0.001). Validation of the model in the PROSELICA (n = 1175) and CARD (n = 126) cabazitaxel-exposed populations confirmed significantly prolonged median OS in the favorable versus intermediate and poor groups (both comparisons p < 0.001). In the overall CARD population (n = 250), cabazitaxel improved OS versus ARPI in the favorable group (p = 0.003), but not in the intermediate or poor groups. CONCLUSIONS AND CLINICAL IMPLICATIONS: The cabascore may help tailor treatment strategy in patients with mCRPC. Exploratory analyses suggest a greater benefit of cabazitaxel in patients with a favorable prognosis versus a second-line ARPI. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT02961257 (CABASTY), NCT01308580 (PROSELICA), NCT02485691 (CARD).
引用
- Vauchier C, Thibault C, Velev M, et al. Integrated Prognostic Score in Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel - A CABASTY Post Hoc Analysis Validated by Two International Prospective Phase 3 Trials. Eur Urol Oncol. 2026. PMID: 42020286. doi:10.1016/j.euo.2026.03.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。